Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is -506.63% as of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
-506.63%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-1105.98%
vs the sector median at left
Caring Brands, Inc.
Market Cap
$11.36M
Return on Equity (ROE)
-506.63%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.55M
Return on Equity (ROE)
-102.40%
TTM Avg
-97.28%
3Y Avg
-110.13%
5Y Avg
-94.77%
Market Cap
$11.12M
Return on Equity (ROE)
-276.21%
TTM Avg
-134.62%
3Y Avg
-196.35%
5Y Avg
-146.45%
Market Cap
$11.08M
Return on Equity (ROE)
-65.18%
TTM Avg
-26.62%
3Y Avg
-94.28%
5Y Avg
-90.35%
Market Cap
$11.02M
Return on Equity (ROE)
-177.35%
TTM Avg
-89.62%
3Y Avg
-75.99%
5Y Avg
-59.80%
Market Cap
$11.00M
Return on Equity (ROE)
N/A
TTM Avg
-43.97%
3Y Avg
-160.70%
5Y Avg
-188.29%
Market Cap
$11.77M
Return on Equity (ROE)
-97.47%
TTM Avg
-90.15%
3Y Avg
-205.18%
5Y Avg
-136.35%
Market Cap
$10.94M
Return on Equity (ROE)
-477.54%
TTM Avg
-207.60%
3Y Avg
64.51%
5Y Avg
-22.91%
Market Cap
$10.86M
Return on Equity (ROE)
-214.92%
TTM Avg
-46.13%
3Y Avg
-156.76%
5Y Avg
-652.77%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caring Brands, Inc. (CABR) | $11.36M | -506.63% | N/A | N/A | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.55M | -102.40% | -97.28% | -110.13% | -94.77% |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.12M | -276.21% | -134.62% | -196.35% | -146.45% |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.08M | -65.18% | -26.62% | -94.28% | -90.35% |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.02M | -177.35% | -89.62% | -75.99% | -59.80% |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | N/A | -43.97% | -160.70% | -188.29% |
| IRIDEX Corporation (IRIX)vs › | $11.77M | -97.47% | -90.15% | -205.18% | -136.35% |
| Cerenome, Inc. (CNSY)vs › | $10.94M | -477.54% | -207.60% | 64.51% | -22.91% |
| BioVie Inc. (BIVI)vs › | $10.86M | -214.92% | -46.13% | -156.76% | -652.77% |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A | -22.56% | -244.57% | 3710.91% |
ROE
-506.6%
ROA
-404.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -506.63% |
